Some medical oncologists contemplate leaving the profession due to COVID-19
Findings from the third ESMO Resilience Task Force survey highlight the detrimental effect of long working hours and changes to clinical routine on future career plans
Rare NETs: sunitinib shows efficacy in pheochromocytoma and paraganglioma
Practice-changing results were also presented in bronchopulmonary and non-pancreatic NETs with somatostatin analogues and VEGFR inhibitors
Can immunotherapy improve the treatment of advanced neuroendocrine neoplasms?
Latest findings on the use of single-agent and combination immunotherapy are not conclusive, despite being promising
New cases of cancer are expected to reach 3.4 million in 2040 in Europe
Projections by the European Commission – Joint Research Centre from Ispra, Italy, estimate a 21.4% increase in cancer cases in 20 years’ time
Novel concepts on the horizon for the diagnosis and treatment of mesothelioma
Malignant pleural mesothelioma is a rare and fatal disease with very little improvement in survival in recent years, mirroring very limited therapeutic advances. After a long-awaited time, improvement in patient survival was achieved with the introduction of nivolumab plus ipilimumab in the first-line setting, as demonstrated in the CheckMate 743 trial.
Molecular profiling holds promise to speed up drug development in rare tumours
Findings from several studies highlight the increasing utility of this approach to identify druggable genetic alterations
Adequate antibody response to SARS-CoV-2 vaccine in patients on chemotherapy or immunotherapy
Most, but not all, patients on chemotherapy or immunotherapy for solid tumours had an adequate immune response after two doses of mRNA-1273 vaccination, with no new safety concerns
Immuno-oncology score predicts response to atezolizumab in TNBC
In the NeoTRIPaPDL1 study, combining information from biomarker analysis at baseline and during treatment was informative on clinical benefit
Multidisciplinary tumour board: poor concordance for tumours with low levels of evidence
A Japanese study reports discrepancies among centres, highlighting the need for better strategies to improve the quality of treatment recommendations
Rare tumours make it to a Presidential Symposium
Rare tumours have been neglected for decades, with lack of funding, lack of research and lack of visibility. It is encouraging to see how this is changing and how research in rare tumours is not only taking place, but also being highlighted in Presidential Symposium 3 at this year’s ESMO Congress.